Market Closed -
Nasdaq
04:00:00 2024-04-25 pm EDT
5-day change
1st Jan Change
0.891
USD
-1.66%
-4.43%
-7.43%
Chimerix, Inc.(NasdaqGM:CMRX) dropped from S&P Biotechnology Select Industry Index
June 21, 2022 at 12:00 am EDT
Chimerix, Inc.(NasdaqGM:CMRX) dropped from S&P Biotechnology Select Industry Index
Chimerix Appoints Marc D. Kozin to Board of Directors
Mar. 21
CI
Transcript : Chimerix, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Feb. 29
Chimerix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 29
CI
Chimerix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 29
CI
Earnings Flash (CMRX) CHIMERIX Reports Q4 Revenue $4,000, vs. Street Est of $70,000
Feb. 29
MT
Chimerix Announces Board Changes
Dec. 29
CI
Chimerix Names Michelle LaSpaluto Finance Chief
Dec. 04
MT
Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer
Dec. 04
CI
Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer
Nov. 16
CI
Transcript : Chimerix, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Nov. 02
Earnings Flash (CMRX) CHIMERIX Posts Q3 Revenue $11,000, vs. Street Est of $90,000
Nov. 02
MT
Chimerix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 02
CI
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery
23-08-16
CI
Transcript : Chimerix, Inc., Q2 2023 Earnings Call, Aug 03, 2023
23-08-03
Earnings Flash (CMRX) CHIMERIX Posts Q2 Revenue $26,000, vs. Street Est of $270,000
23-08-03
MT
Chimerix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-03
CI
Chimerix Names Michael Andriole as Chief Executive Officer
23-06-27
MT
Chimerix, Inc. Announces CEO Changes, Effective on August 1, 2023
23-06-27
CI
Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023
23-06-27
CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell Small Cap Comp Value Index
23-06-23
CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 3000 Index
23-06-23
CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell Small Cap Completeness Index
23-06-23
CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2500 Value Index
23-06-23
CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2500 Index
23-06-23
CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
More about the company
Last Close Price
0.906
USD
Average target price
7.333
USD
Spread / Average Target
+709.42%
Consensus
1st Jan change
Capi.
-7.43% 80.82M -2.26% 104B +1.41% 97.42B +0.79% 22.2B -17.84% 21.23B -11.11% 18.33B -42.83% 16.35B -17.63% 15.06B +4.55% 13.98B +32.11% 11.66B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
CHIMERIX, INC. 
